Biggest News Aggregation in the World
๐Ÿ“ฐ Bph News

Page 196 - Bph News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Bph. Real-time updates on events, politics, business and more.

Parker-Hannifin Co. (NYSE:PH) VP Sells $859,432.95 in Stock

Parker-Hannifin Co. (NYSE:PH – Get Rating) VP William R. Bowman sold 2,403 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $357.65, for a total value of $859,432.95. Following the completion of the transaction, the vice president now directly owns 11,152 shares of […]
Robertw Baird Williamr Bowman Prudential Plc Cetera Advisor Networks Vanguard Group Inc Wells Fargo Company

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Public Employees Retirement Association of Colorado Sells 50 Shares of Parker-Hannifin Co. (NYSE:PH)

Public Employees Retirement Association of Colorado trimmed its holdings in shares of Parker-Hannifin Co. (NYSE:PH – Get Rating) by 0.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,779 shares of the industrial products company’s stock after selling […]
United States Stifel Nicolaus Markt Czaja Robertw Baird Exchange Commission Forum Financial Management

Dr Jabbour on the Efficacy of Ponatinib in Newly Diagnosed Ph+ ALL

Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosomeโ€“positive acute lymphoblastic leukemia.
United States Elias Jabbour Division Of Cancer Medicine Department Of Leukemia University Of Texas Md Anderson Cancer Center Cancer Medicine

Dr Bardia on Results of the NATALEE Trial in HR+/HER2– Early Breast Cancer

Aditya Bardia, MD, MPH, discusses the investigation of ribociclib and endocrine therapy vs endocrine therapy alone as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer, highlighting primary results from the phase 3 NATALEE trial.
United States Aditya Bardia Harvard Medical School Massachusetts General Hospital Onclive Tv Breast Cancer

Gyon Technologies Capital Management LP Invests $2.56 Million in Parker-Hannifin Co. (NYSE:PH)

Gyon Technologies Capital Management LP purchased a new position in shares of Parker-Hannifin Co. (NYSE:PH – Get Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,812 shares of the industrial products company’s stock, valued at approximately $2,564,000. Parker-Hannifin accounts for about 1.0% […]
Robertw Baird Stifel Nicolaus Markt Czaja Deutsche Bank Aktiengesellschaft Parker Hannifin Co Parker Hannifin Corp

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science